Abstract
Neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs) are different tumor categories with no pathogenetic, morphologic, clinical, or therapeutic similarities: NETs are epithelial to neural tumors in contrast to GISTs, which show mesenchymal cell lineage. Both tumors, however, arise more frequently from the gastrointestinal tract and may benefit of specific target therapeutic approaches: imatinib/STI-571 for GISTs and m-Tor pathway inhibitors or somatostatin analogs for NETs. The role of pathologist is crucial when dealing with both NETs and GISTs, as morphological, immunohistochemical, and molecular analysis often provide helpful information on the clinical behavior and management. We here propose a general overview on nomenclature of tumors classification and suggestions for histological report of both NETs and GISTs. Moreover, we will approach in finer details the immunohistochemical analysis on origin and differential diagnosis in NETs as well as the prognosis and resistance to therapy in GISTs. This review emphasized recent literature advances regarding similarities and differences in the managerial pathologist's approach to either tumor type.
| Original language | English |
|---|---|
| Pages (from-to) | 9-31 |
| Number of pages | 23 |
| Journal | Journal of OncoPathology |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- CD117
- Cdx-2 GIST
- Isl-1
- KIT
- NET
- Neuroendocrine tumor
- PDGFRA
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Pathology and Forensic Medicine
Cite this
Is the pathologist indispensable in gastrointestinal stromal tumors and neuroendocrine tumors? / Milione, Massimo; Pilotti, Silvana; Pelosi, Giuseppe.
In: Journal of OncoPathology, Vol. 2, No. 3, 2014, p. 9-31.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is the pathologist indispensable in gastrointestinal stromal tumors and neuroendocrine tumors?
AU - Milione, Massimo
AU - Pilotti, Silvana
AU - Pelosi, Giuseppe
PY - 2014
Y1 - 2014
N2 - Neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs) are different tumor categories with no pathogenetic, morphologic, clinical, or therapeutic similarities: NETs are epithelial to neural tumors in contrast to GISTs, which show mesenchymal cell lineage. Both tumors, however, arise more frequently from the gastrointestinal tract and may benefit of specific target therapeutic approaches: imatinib/STI-571 for GISTs and m-Tor pathway inhibitors or somatostatin analogs for NETs. The role of pathologist is crucial when dealing with both NETs and GISTs, as morphological, immunohistochemical, and molecular analysis often provide helpful information on the clinical behavior and management. We here propose a general overview on nomenclature of tumors classification and suggestions for histological report of both NETs and GISTs. Moreover, we will approach in finer details the immunohistochemical analysis on origin and differential diagnosis in NETs as well as the prognosis and resistance to therapy in GISTs. This review emphasized recent literature advances regarding similarities and differences in the managerial pathologist's approach to either tumor type.
AB - Neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs) are different tumor categories with no pathogenetic, morphologic, clinical, or therapeutic similarities: NETs are epithelial to neural tumors in contrast to GISTs, which show mesenchymal cell lineage. Both tumors, however, arise more frequently from the gastrointestinal tract and may benefit of specific target therapeutic approaches: imatinib/STI-571 for GISTs and m-Tor pathway inhibitors or somatostatin analogs for NETs. The role of pathologist is crucial when dealing with both NETs and GISTs, as morphological, immunohistochemical, and molecular analysis often provide helpful information on the clinical behavior and management. We here propose a general overview on nomenclature of tumors classification and suggestions for histological report of both NETs and GISTs. Moreover, we will approach in finer details the immunohistochemical analysis on origin and differential diagnosis in NETs as well as the prognosis and resistance to therapy in GISTs. This review emphasized recent literature advances regarding similarities and differences in the managerial pathologist's approach to either tumor type.
KW - CD117
KW - Cdx-2 GIST
KW - Isl-1
KW - KIT
KW - NET
KW - Neuroendocrine tumor
KW - PDGFRA
UR - http://www.scopus.com/inward/record.url?scp=84906982772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906982772&partnerID=8YFLogxK
U2 - 10.13032/tjop.2052-5931.100094
DO - 10.13032/tjop.2052-5931.100094
M3 - Article
VL - 2
SP - 9
EP - 31
JO - Journal of OncoPathology
JF - Journal of OncoPathology
SN - 2052-5931
IS - 3
ER -